Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Accumulated Expenses (2016 - 2025)

Marimed (MRMD) has disclosed Accumulated Expenses for 13 consecutive years, with $9.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Accumulated Expenses rose 43.82% to $9.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.0 million, a 43.82% increase, with the full-year FY2024 number at $4.4 million, up 24.96% from a year prior.
  • Accumulated Expenses was $9.0 million for Q3 2025 at Marimed, up from $7.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $11.1 million in Q3 2021 to a low of $1.7 million in Q1 2022.
  • A 5-year average of $5.2 million and a median of $4.6 million in 2024 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 256.59% in 2021, then crashed 70.57% in 2022.
  • Marimed's Accumulated Expenses stood at $3.1 million in 2021, then dropped by 1.84% to $3.1 million in 2022, then rose by 14.82% to $3.5 million in 2023, then increased by 24.96% to $4.4 million in 2024, then surged by 103.52% to $9.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRMD's Accumulated Expenses are $9.0 million (Q3 2025), $7.4 million (Q2 2025), and $7.7 million (Q1 2025).